← Back to Patent Explorer
US4436738A Expired / Lapsed US ⏱️ 0.0 years remaining

Stabilized estradiol cream composition

Assignee: Warner Chilcott Co LLC
•
Filing: 1982-03-15
•
Granted: 1984-03-13
•
Expires: 2002-03-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Loss of potency of estradiol cream compositions found to be due to unexpected oxidation of estradiol. Improved cream composition comprises 1% or less 17β-estradiol in the presence of stabilizing members selected from phenolic-type antioxidants, metal chelating agents, and suspending agents.

Inventors

  • 👤 Robert J. Bequette
  • 👤 Linda G. Hobbs
  • 👤 Joseph A. Scott

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 23:17
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/56; A61K31/565

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 119 words
A cream composition for topical estrogen therapy which comprises 17β-estradiol of a concentration of about 1% or less on a weight basis relative to the whole composition and the remainder being a pharmaceutically acceptable carrier wherein said carrier contains as stabilizers from about 0.01 to about 10% by weight of at least one member selected from (a) one or more phenolic-type antioxidants selected from the group consisting of t-butylhydroquinone, di-t-amylhydroquinone, di-t-butylhydroquinone, butylhydroxytoluene, butylhydroxyanisole, pyrocatechol, pyrogallol, propyl gallate, and nordihydroguaiaretic acid; (b) one or more metal chelating agents selected from the group consisting of the sodium edetates (EDTA), and edatic acid; and (c) one or more suspending agents selected from the group consisting of carbomer, carboxymethylcellulose, hydroxypropyl methylcellulose and methylcellulose.
Claim 2
Dependent Claim 119 words
A cream composition for topical estrogen therapy which comprises 17β-estradiol of a concentration of about 1% or less on a weight basis relative to the whole composition and the remainder being a pharmaceutically acceptable carrier wherein said carrier contains as stabilizers from about 0.01 to about 10% by weight of at least one member selected from (a) one or more phenolic-type antioxidants selected from the group consisting of t-butylhydroquinone, di-t-amylhydroquinone, di-t-butylhydroquinone, butylhydroxytoluene, butylhydroxyanisole, pyrocatechol, pyrogallol, propyl gallate, and nordihydroguaiaretic acid; (b) one or more metal chelating agents selected from the group consisting of the sodium edetates (EDTA), and edatic acid; and (c) one or more suspending agents selected from the group consisting of carbomer, carboxymethylcellulose, hydroxypropyl methylcellulose and methylcellulose.
Claim 3
Dependent Claim 71 words
The composition of claim 1 wherein the concentration of antioxidant is less than 0.1% by weight; the metal chelating agent is a sodium edetate which is present in a concentration of less than 0.1% by weight; at least one of the suspending agents is present in a concentration of 1% or less; and 17β-estradiol is present at a 0.1% or less concentration on a weight basis relative to the whole composition.
Claim 4
Dependent Claim 67 words
The composition of claim 1 wherein the antioxidant is tertiary butylhydroquinone at a concentration of 0.2 parts per 1,000 parts cream; the metal chelating agent is disodium edetate at a concentration of 0.5 part per 1,000 parts cream; the suspending agent is hydroxypropyl methylcellulose at a concentration of 3 parts per 1,000 parts cream and 17β-estradiol is at the concentration of 0.1 part per 1,000 parts cream.
Claim 5
Dependent Claim 44 words
The composition as recited in claim 3 which further comprises per 1,000 parts cream: stearyl alcohol, 70 parts; glyceryl monostearate, 40 parts; white ceresin wax, 70 parts; sodium lauryl sulfate, 3 parts; methylparaben, 1.5 parts; propylene glycol, 100 parts; and purified water, 712 parts.

References Cited (Backward Citations)

US2096744A Cited
US4154820A Cited
US4344940A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-03-13 1987-09-12 1988-03-13 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-03-13 1991-09-12 1992-03-13 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-03-13 1995-09-12 1996-03-13 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag